NCT05290363 The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
| NCT ID | NCT05290363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Spondyloarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2022-10-06 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2022-10-06 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
Eligibility Criteria
Inclusion Criteria: * Age : Adults (\>18 years) * Satisfying ASAS diagnostic criteria for SpA * Patient has active disease, defined by the presence of active synovitis, tendinitis, or dactylitis or significant inflammatory pain of the spine, judged by the examining clinician to be due to SpA. * Informed consent signed * Beneficiary of health insurance, except for the AME Only for patients of Group 1 • Patient is naïve to biological therapies Only for patients of Group 2 * Patient is affected by peripheral SpA (ASAS criteria) or psoriatic arthritis, with inflammation of peripheral joints * Patient requires aspiration, as part of standard care Non inclusion criteria: * Patient is minor * Patient is pregnant or breastfeeding * Patient is immunocompromised * Patient has received biological therapy with 2 or more biologics * Patient is receiving corticosteroid treatment \> 10 mg per day * Patient is under legal protection, curators, guardianship * Patient refuses consent * Previous history of alcoholism, drug addiction, psychological problems, severe concomitant conditions that could invalidate the patient's consent or limit the patient's compliance to the treatment protocol. * Beneficiary of the AME Only for group 1 • Patient has received biological therapy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05290363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Spondyloarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05290363 currently recruiting?
Yes, NCT05290363 is actively recruiting participants. Contact the research team at lars.rogge@pasteur.fr for enrollment information.
Where is the NCT05290363 trial being conducted?
This trial is being conducted at Créteil, France, Paris, France, Paris, France, Reims, France.
Who is sponsoring the NCT05290363 clinical trial?
NCT05290363 is sponsored by Institut Pasteur. The trial plans to enroll 90 participants.